Paradigm Biocapital Advisors LP Mirati Therapeutics, Inc. Transaction History

Paradigm Biocapital Advisors LP

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	SELL	$41.99 - $62.38 $5.25 Million - $7.8 Million	-125,000 Reduced 7.49%	1,543,116 $90.7 Million
Q3 2023 Nov 14, 2023	BUY	$27.8 - $45.35 $6.24 Million - $10.2 Million	224,354 Added 15.54%	1,668,116 $72.7 Million
Q2 2023 Aug 14, 2023	BUY	$36.13 - $49.49 $1.7 Million - $2.33 Million	46,983 Added 3.36%	1,443,762 $52.2 Million
Q1 2023 May 15, 2023	BUY	$36.54 - $54.26 $4.71 Million - $6.99 Million	128,809 Added 10.16%	1,396,779 $51.9 Million
Q4 2022 Feb 14, 2023	BUY	$41.27 - $98.62 $17.2 Million - $41.2 Million	417,585 Added 49.11%	1,267,970 $57.5 Million
Q3 2022 Nov 14, 2022	BUY	$59.5 - $86.7 $11.3 Million - $16.5 Million	190,417 Added 28.85%	850,385 $59.4 Million
Q2 2022 Aug 15, 2022	BUY	$39.16 - $88.71 $22 Million - $49.8 Million	561,585 Added 570.82%	659,968 $44.3 Million
Q1 2022 May 16, 2022	SELL	$75.82 - $150.97 $12.3 Million - $24.4 Million	-161,732 Reduced 62.18%	98,383 $8.09 Million
Q4 2021 Feb 14, 2022	BUY	$132.01 - $190.29 $34.3 Million - $49.5 Million	260,115 New	260,115 $38.2 Million

3.57M

36.6K

Ticker MRTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 55,609,800
Description
Mirati Therapeutics, Inc., a clinical-stage oncology company, develops product candidates to address the genetic and immunological promoters of cancer in the United States. The company develops MRTX849, a KRAS G12C inhibitor, which is in Phase 1/2 clinical trial for treating non-small cell lung (NSCL), colorectal, pancreatic, and other cancers; ...

Get notified when there are updates to the investment portfolio of Paradigm Biocapital Advisors LP, based on Form 13F filings with the SEC.

Stay updated on Paradigm Biocapital Advisors LP with notifications on news.